Can CA125 (Cancer Antigen 125) levels detect endometriosis in a female patient of reproductive age?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 29, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

CA125 Cannot Reliably Detect Endometriosis

CA125 has limited utility as a diagnostic marker for endometriosis, particularly in minimal and mild disease, and should not be used as a screening or diagnostic test in women presenting with suspected endometriosis. The American College of Obstetricians and Gynecologists explicitly states that serum CA125 levels as a diagnostic marker are limited, especially in women with mild or minimal disease 1.

Diagnostic Performance

The diagnostic accuracy of CA125 for endometriosis is poor:

  • Sensitivity ranges from only 24-94% with specificity of 83-93%, making it unreliable for detecting disease 2
  • Only 27% of minimal endometriosis cases and 68% of mild cases show elevated CA125, compared to 73% of moderate and 100% of severe cases 3
  • Using a cutoff of 16 U/ml, CA125 demonstrates 53% sensitivity and 93% specificity—missing nearly half of all cases 3
  • A newer second-generation CA125 assay showed no dramatic improvement in detecting endometriosis compared to older assays 4

Clinical Context and Limitations

CA125 elevation is non-specific and occurs in multiple benign conditions:

  • Endometriosis, pelvic inflammatory disease, adenomyosis, menstruation, and other benign ovarian cysts all elevate CA125 1, 5
  • The American College of Radiology emphasizes that elevated CA125 in a premenopausal patient with clinical features suggesting endometriosis should not raise concern for malignancy 5
  • CA125 levels fluctuate with the menstrual cycle in women with advanced endometriosis, rising during the luteal phase and menstruation 6

Limited Clinical Applications

While CA125 cannot diagnose endometriosis, it has narrow utility in specific scenarios:

  • For deeply infiltrating endometriosis types II and III, CA125 shows 36% sensitivity and 87% specificity—useful only for the most severe forms that are clinically difficult to detect 6
  • In women with advanced endometriosis and initially elevated CA125, the marker may help monitor for recurrence after treatment, with 84% correlation with clinical course 3
  • CA125 measurement in ovarian cyst fluid (not serum) can differentiate corpus luteum cysts from endometriotic cysts 6

Critical Pitfall to Avoid

Do not use CA125 to monitor therapy response—ten women with persistent endometriosis confirmed by laparoscopy during danazol treatment had normal CA125 levels (<35 U/ml), demonstrating that normal values do not exclude active disease 7. CA125 is not effective for monitoring therapy 7.

Recommended Diagnostic Approach

Histologic examination via laparoscopy with tissue biopsy remains the gold standard for diagnosing endometriosis 1. The ACOG committee states that only experienced surgeons familiar with the varied appearances of endometriosis should rely on visual inspection alone; otherwise, peritoneal biopsy is required 1.

For women with unexplained pelvic pain, CA125 may be considered as an adjunct to identify deeply infiltrating disease that might otherwise be missed clinically 6, but never as a primary diagnostic tool or to rule out endometriosis.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Laboratory testing for endometriosis.

Clinica chimica acta; international journal of clinical chemistry, 2004

Research

Use of a new CA 125 assay in the diagnosis of endometriosis.

Human reproduction (Oxford, England), 1995

Guideline

CA125 Elevation in Endometriosis Diagnosis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

CA 125 in the management of endometriosis.

European journal of obstetrics, gynecology, and reproductive biology, 1993

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.